Our results are very preliminary because we began the treatments on the larger group of patients in January of this year, so we have only some months of experience on the bigger group of patients. I think we will have full data in the autumn, after the half-year, after the treatment.
But what I can say now about what we are seeing after one or two months of the treatment is that about 80%, 90%, of the patients experience improvement, and many of the patients are progressive multiple sclerosis patients with no options for treatment. Many of them have no possibility to have effective pharmacological treatment. For these patients, it's really a big thing, but of course, as I said, our data is very incomplete and primary.